By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video

Key Statistics

Ownership: Public

Web Site: Actavis
Symbol: ACT


Company News
Actavis (ACT) and Adamas Pharmaceuticals (ADMS) Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 12/24/2014 6:40:53 AM
Actavis (ACT), Adamas Pharmaceuticals (ADMS) Win FDA Approval for Alzheimer's Drug Namzaric 12/24/2014 6:39:42 AM
Actavis (ACT) Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 12/22/2014 9:32:33 AM
Actavis (ACT)To Present At 33rd Annual J.P. Morgan Healthcare Conference 12/22/2014 7:47:55 AM
Actavis (ACT) Release: XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion For The Treatment Of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) In Adults 12/22/2014 7:38:43 AM
Spending Spree Continues as Actavis (ACT) Considers Near $3 Billion Bid for Almirall 12/22/2014 6:05:44 AM
Actavis (ACT) To Present At The Goldman, Sachs & Co. Healthcare CEOs Unscripted Conference 12/19/2014 9:43:41 AM
Actavis (ACT) Purges Most Allergan (AGN) Execs In Takeover 12/16/2014 10:21:40 AM
Actavis (ACT) Announces Proposed Senior Leadership Team Effective Following Completion Of Allergan (AGN) Acquisition 12/16/2014 8:17:05 AM
Actavis (ACT) Will Appeal Injunction Requiring Continued Distribution Of NAMENDA IR 12/16/2014 7:49:49 AM